Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0721-5186 · 1 trial · 2 indications
Measured in number of events.
| Arm | Type | Description |
|---|---|---|
| NNC0721-5186 | EXPERIMENTAL | Participants will receive a single ascending subcutaneous dose of NNC0721-5186. |
| Semaglutide | ACTIVE_COMPARATOR | Participants will receive a single ascending subcutaneous dose of semaglutide up to 3 doses. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive a single ascending subcutaneous dose of placebo matched to NNC0721-5186. |
| Name | Type | Description |
|---|---|---|
| NNC0721-5186 | DRUG | NNC0721-5186 is administered as a single subcutaneous injection. |
| Semaglutide | DRUG | Semaglutide is administered as a single subcutaneous injection using a pen-injector. |
| Placebo (NNC0721-5186) | DRUG | Placebo is administered as a single subcutaneous injection matching NNC0721-5186. |
Inclusion Criteria: 1. Female (sex at birth). 2. Age 18 to 55 years (both inclusive) at the time of signing the informed consent. 3. Body Mass Index 25.0 to 39.9 kg/m\^2 (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator. 4. Considered eligible...